Romosozumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | Sclerostin |
| Clinical data | |
| Trade names | Evenity |
| Other names | AMG 785, romosozumab-aqqg |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619026 |
| License data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6452H9926N1714O2040S54 |
| Molar mass | 145877.58 g·mol−1 |
  (what is this?) (verify) | |
Romosozumab, sold under the brand name Evenity, is a medication used to treat osteoporosis.[1] It has been found to decrease the risk of fractures of the spine.[1]
Common side effect include headache, joint pain, and pain at the site of injection.[1] It may increase the risk of heart attacks, strokes, and deaths from cardiovascular disease.[1] It is a humanized monoclonal antibody that targets sclerostin.[2] Research shows the drug increases bone formation and decreases bone resorption in postmenopausal women with low bone density. Romosozumab was approved for medical use in Japan, the United States and the European Union in 2019.[1][3][4]
Medical uses
Romosozumab is used for osteoprosis to decrease the risk of fractures.[3] Two trials found that it reduced the rate of vertebral fracture. In one, there was a 73% lower risk of vertebral fracture after one year, and the benefit was maintained after a second year of taking denosumab. In the other, one year of romosozumab followed by one year of alendronate had a 50% vertebral fracture reduction compared to two years of alendronate.[3]
Side effects
Common side effects include headache, joint pain, and pain at the site of injection.[1] It may increase the risk of heart attacks, strokes, and deaths from cardiovascular disease.[1]
History
Romosozumab was approved for medical use in Japan in January 2019,[3] the United States in April 2019[3] and the European Union in December 2019.[4] It was originally discovered by Chiroscience,[5] which was acquired by Celltech (now[when?] owned by UCB).[6] Celltech entered in a partnership with Amgen in 2002 for the product's development.[7]
References
- ^ a b c d e f g "FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture". U.S. Food and Drug Administration (FDA) (Press release). 9 April 2019. Retrieved 12 April 2019.
{{cite press release}}:|archive-date=requires|archive-url=(help)CS1 maint: url-status (link) - ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Romosozumab" (PDF). American Medical Association. Archived from the original (PDF) on 29 September 2012.
- ^ a b c d e Kaplon H, Muralidharan M, Schneider Z, Reichert JM (2020). "Antibodies to watch in 2020". MAbs. 12 (1): 1703531. doi:10.1080/19420862.2019.1703531. PMC 6973335. PMID 31847708.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ a b Victoria Rees (13 December 2019). "EC approves treatment for severe osteoporosis postmenopausal women". European Pharmaceutical Review. Retrieved 27 February 2020.
- ^ Quested, Tony (7 June 2015). "Cream of life science entrepreneurs' first venture was selling doughnuts". Business Weekly. Cambridge, England: Q Communications. Retrieved 24 December 2018.
{{cite news}}: Unknown parameter|name-list-format=ignored (|name-list-style=suggested) (help) - ^ Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, et al. (December 2003). "Osteocyte control of bone formation via sclerostin, a novel BMP antagonist". The EMBO Journal. 22 (23): 6267–6276. doi:10.1093/emboj/cdg599. PMC 291840. PMID 14633986.
- ^ "Celltech group Interim Report 2002" (PDF). Celltech Group plc.
External links
- "Romosozumab". Drug Information Portal. U.S. National Library of Medicine.
- "Drug Trials Snapshot: Evenity". U.S. Food and Drug Administration (FDA).
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |